Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Common Equity (2019 - 2025)

Lyell Immunopharma (LYEL) has disclosed Common Equity for 7 consecutive years, with $248.2 million as the latest value for Q4 2025.

  • Quarterly Common Equity fell 35.17% to $248.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $248.2 million through Dec 2025, down 35.17% year-over-year, with the annual reading at $248.2 million for FY2025, 35.17% down from the prior year.
  • Common Equity hit $248.2 million in Q4 2025 for Lyell Immunopharma, down from $329.1 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $1.0 billion in Q2 2021 to a low of -$334.0 million in Q1 2021.
  • Historically, Common Equity has averaged $608.8 million across 5 years, with a median of $676.3 million in 2023.
  • Biggest five-year swings in Common Equity: soared 525.62% in 2021 and later crashed 47.23% in 2025.
  • Year by year, Common Equity stood at $929.8 million in 2021, then dropped by 10.38% to $833.3 million in 2022, then dropped by 21.4% to $655.0 million in 2023, then tumbled by 41.55% to $382.8 million in 2024, then crashed by 35.17% to $248.2 million in 2025.
  • Business Quant data shows Common Equity for LYEL at $248.2 million in Q4 2025, $329.1 million in Q3 2025, and $298.9 million in Q2 2025.